IJMS | Free Full-Text | Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives | HTML
Full article: Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials
Molecular targeted therapies: Ready for “prime time” in biliary tract cancer - Journal of Hepatology
Targeting FGFR inhibition in cholangiocarcinoma - Cancer Treatment Reviews
Clinical Trials | Research Study | MedStar Health
Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There? | Clinical Cancer Research
An introduction to planning for HTA for tumour-agnostic cancer drugs – BresMed
Petros Grivas on Twitter: "@IyerGopa presented on FGFRi in urothelial Ca including fda-approved erdafitinib & other agents, e.g. infigratinib adjuvant trial & Fuze trial for FGFR fusions! Debate ongoing on FGFR alterations
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q - Annals of Oncology
Study history - Phase1
The cyclophilin inhibitor Debio‐025 shows potent anti–hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus - Flisiak - 2008 - Hepatology - Wiley Online Library
ESMO 2020 Preview, part 2: new and/or notable | BLU Ampersand, Inc.
Therapy for Advanced or Metastatic Cholangiocarcinoma | OTT
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study - ScienceDirect
Systemic therapies for intrahepatic cholangiocarcinoma - Journal of Hepatology
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study - The Lancet Oncology
Beyond Cancer Type: New Pan-Tumor Targets Emerge
Debio 1143-SCCHN-301 – Gettysburg Cancer Center
Debiopharm and 3BP enter into global R&D deal for radioligand tech
Pharmaceuticals | Free Full-Text | TRK Inhibitors: Tissue-Agnostic Anti-Cancer Drugs | HTML
Debio 1143-SCCHN-301 – Gettysburg Cancer Center
Cells | Free Full-Text | New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma | HTML
